| Monday, January 03 2011 |
|
MIVAC Development receives verification grant from GöteborgBIO and Sahlgrenska Science Park (SSP). The grant will enable MIVAC Development to further develop and verify the therapeutic and commercial potential of a newly discovered monoclonal antibody specific for the toxic confomation of Aβ aggregates. The antibody was developed using the AβCCTM technology platform (patent pending approval). Click here to view the GöteborgBIO/SSP press release (in swedish). |
MIVAC Development has decided to no longer pursue the project for the development of a new vaccine against gastric ulcer and gastric cancer.
Read more >>>
MIVAC Development creates a new company, Toleranzia AB, for the spin-out of the tolerance inducing Re-TolerogenTM platform.
Read more >>>
MIVAC development receives continued financial support from Innovationskontor Väst for the tolerance inducing Re-TolerogenTM platform.
MIVAC Development creates a new company, Alzinova AB, for the spin-out of the AβCCTM-project.
Read more >>>